Canal Insurance CO Trims Stock Position in CVS Health Corporation $CVS

Key Points

• Canal Insurance CO reduced its stake in CVS by 52.4% in Q4, selling 110,000 shares and retaining 100,000 shares worth $7.94 million, making CVS its 18th largest holding (~1.9% of the portfolio).
• CVS beat Q1 estimates—reporting $2.57 EPS vs. $2.21 expected and $100.43B revenue vs. $94.99B—and raised FY2026 adjusted EPS guidance to $7.30–$7.50, prompting several analyst price‑target increases and a consensus "Moderate Buy."
• CVS pays a quarterly dividend of $0.665 (annualized $2.66) for about a 3.0% yield

Canal Insurance CO lessened its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 52.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the pharmacy operator's stock after selling 110,000 shares during the period. CVS Health accounts for approximately 1.9% of Canal Insurance CO's portfolio, making the stock its 18th largest holding. Canal Insurance CO's holdings in CVS Health were worth $7,936,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of CVS. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Corundum Trust Company INC purchased a new stake in shares of CVS Health in the third quarter valued at about $29,000. Ares Financial Consulting LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at about $29,000. GoalVest Advisory LLC purchased a new stake in shares of CVS Health in the fourth quarter valued at about $32,000. Finally, Financial Consulate Inc. lifted its holdings in shares of CVS Health by 99.6% in the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator's stock valued at $40,000 after purchasing an additional 249 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of CVS opened at $87.34 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market capitalization of $111.93 billion, a price-to-earnings ratio of 38.47, a PEG ratio of 0.91 and a beta of 0.60. The company's 50 day simple moving average is $76.86 and its 200 day simple moving average is $78.03. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $88.63.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the business posted $2.25 earnings per share. CVS Health's revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 3.0%. CVS Health's dividend payout ratio is 192.75%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 earnings and guidance beat — CVS reported Q1 adjusted EPS of $2.57 and revenue of $100.4B, topped estimates and raised full‑year 2026 adjusted EPS guidance to $7.30–$7.50, driven by insurance margin improvement and reserve benefits. This is the primary catalyst lifting the stock. CVS Health raises 2026 forecast after improving medical cost controls
• Positive Sentiment: Broker optimism and price-target increases — Multiple firms (Truist, UBS, DA Davidson, Deutsche Bank and others) bumped price targets and reiterated/maintained buy ratings, signaling analyst confidence that improved insurance performance and guidance justify higher valuation. Benzinga Deutsche Bank adjusts CVS Health price target DA Davidson raises price target
• Positive Sentiment: Improving insurance (Aetna) profitability — Management cited lower medical benefit ratios and better cost controls in government plans; Aetna’s turnaround is driving margin expansion and was highlighted repeatedly on the call. CVS blows past estimates, hikes outlook as insurance business outperforms
• Positive Sentiment: Retail operations showing strength — Increased prescription volume and retail pharmacy trends supported revenue growth and margin expansion, reinforcing the diversified earnings base. CVS’s increased prescription volume leads to solid Q1
• Neutral Sentiment: Strategic initiatives (biosimilars, AI, community programs) — CVS announced wider biosimilar formulary adoption and AI-driven affordability programs that could lower costs and boost long‑term margins, but near‑term impact is gradual. CVS Health Bets On Biosimilars And AI To Support Affordable Care
• Neutral Sentiment: Economic/PR pieces — Reports on CVS’s large national economic footprint and community programs support brand and regulatory goodwill but have limited immediate share‑price impact. CVS Health's Annual Impact in Connecticut
• Negative Sentiment: Valuation and structural PBM concerns — Some analysts and industry pieces warn that a temporary insurance profitability tailwind may mask longer‑term margin pressure in the PBM/business transformation, suggesting upside may be capped until sustainable improvement is proven. How CVS Health's Transformation Is Facing A Hard Valuation Floor

Wall Street Analysts Forecast Growth

CVS has been the topic of several recent research reports. Leerink Partners reaffirmed an "outperform" rating and issued a $98.00 price target on shares of CVS Health in a report on Thursday, March 5th. Argus reduced their price objective on shares of CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a research note on Wednesday, January 28th. Truist Financial upped their price objective on shares of CVS Health from $98.00 to $102.00 and gave the company a "buy" rating in a research note on Thursday. Sanford C. Bernstein raised shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $91.00 to $94.00 in a research note on Thursday, March 12th. Finally, The Goldman Sachs Group upped their price objective on shares of CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a research note on Thursday, February 12th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.88.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.